

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/256507 A1

(43) International Publication Date
08 December 2022 (08.12.2022)

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:
PCT/US2022/031927

(22) International Filing Date:
02 June 2022 (02.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/196,763 04 June 2021 (04.06.2021) US

(71) Applicant: **IMMUNOGEN, INC.** [US/US]; 830 Winter Street, Waltham, Massachusetts 02451 (US).

(72) Inventors: **WESTIN, Eric**; c/o ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451 (US). **WANG, Jiuzhou**; c/o ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451 (US). **SLOSS, Callum**; c/o ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451 (US).

(74) Agent: **STEFFE, Eric K.** et al.; STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA

(57) Abstract: The present disclosure demonstrates that the amount of soluble folate receptor alpha (FR α) present in a cancer patient is a strong predictor of the efficacy of FR α -targeting therapies. Surprisingly, increased levels of soluble FR α are associated with improved outcomes. Accordingly, the present disclosure provides methods for treating cancer in patients with soluble FR α and methods for identifying a cancer as likely to respond to an anti-FR α therapy based on soluble FR α levels.

WO 2022/256507 A1